HITCH: Preclinical Brain Tumor Models

Sponsor

Assistance Publique Hopitaux De Marseille (Other)

Overall Status

Recruiting

CT.gov ID

NCT06045065

Collaborator

(none)

Enrollment

Location

Anticipated Duration (Months)

1.7

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Background: Primary or secondary brain tumors (metastases) remain associated with a very poor prognosis linked to significant therapeutic resistance. Thus, glioblastoma, which is the most common and aggressive primary brain tumor in adults, is associated with inevitable relapses within 7 to 10 months and median survival of approximately 12 to 14 months. At the same time, brain metastases are increasingly increasing following better systemic control of other metastatic sites and improvement in detection methods. However, they remain resistant to the latest therapeutic innovations such as immunotherapies or targeted therapies.

In this context, innovative strategies are necessary to identify new therapeutic targets and implement new treatments to overcome resistance phenomena in the clinic.

Objective: Our goal will be to generate tumoroids and stem-like cell lines (PDX) from patient tumor samples.

Methods: We will establish tumor tumoroids and stem cell lines from patient samples. These preclinical models will allow us to test a large number of drugs, quickly and efficiently thanks to models as close as possible to patient tumors and limiting the use of animal models (3R).

Overall, this project should enable major advances in the treatment of glioblastoma and brain metastases and enable the rapid testing of new molecules in clinical trials thanks to the homology of our models with our patients' diseases.

Condition or Disease	Intervention/Treatment	Phase
Brain Metastases Diffuse Gliomas	Other: Fresh tumor sampling

Study Design

Study Type:

Observational

Anticipated Enrollment :

60 participants

Observational Model:

Other

Time Perspective:

Prospective

Official Title:

Establishment of Pre-clinical Stem Line and Tumoroid Models of Brain Tumors

Actual Study Start Date :

Jan 2, 2022

Anticipated Primary Completion Date :

Jan 1, 2024

Anticipated Study Completion Date :

Jan 1, 2025

Arms and Interventions

Arm	Intervention/Treatment
patients with primitive tumor Patient samples will be collected during routine care neurosurgical resection.	Other: Fresh tumor sampling Patient samples will be collected during neurosurgical resection. .
patients with brain metastasis Patient samples will be collected during routine care neurosurgical resection.	Other: Fresh tumor sampling Patient samples will be collected during neurosurgical resection. .

Arm

Intervention/Treatment

patients with primitive tumor

Patient samples will be collected during routine care neurosurgical resection.

Other: Fresh tumor sampling

Patient samples will be collected during neurosurgical resection. .

patients with brain metastasis

Patient samples will be collected during routine care neurosurgical resection.

Other: Fresh tumor sampling

Patient samples will be collected during neurosurgical resection. .

Outcome Measures

Primary Outcome Measures

Tumoroid and stem cell line generation [4 weeks after generation]
The generation of tumoroids and stem cell lines will be attested at 4 weeks after initiation of their culture. Tumoroids: generation of round and viable structures Stem cell lines: generation of neurospheres